Research and Markets: Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential Despite Moderate Scope of Current Late Stage Molecules.
GBI Research, the leading business intelligence provider, has released its latest research Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules, which provides insights into the Oncology orphan disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The report examines the global orphan diseases therapeutics in Oncology usage patterns. It includes the geographical distribution of pancreatic cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia and Hodgkin lymphoma markets across the US, the top five European countries and in Japan. The report also includes insights into the orphan diseases therapeutics in Oncology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the Oncology orphan disease therapeutics market.
- Data and analysis on the orphan diseases therapeutics in oncology market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain and Japan.
- Annualized market data for the orphan diseases therapeutics in oncology market from 2004 to 2010, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Celgene Corporation, Genentech, Inc, Amgen, Eli Lilly and Company, Takeda.
- Celgene Corporation
- Genentech, Inc.
- Amgen, Inc.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Ltd.
For more information visit http://www.researchandmarkets.com/research/nv7t3r/orphan_diseases_th
|Printer friendly Cite/link Email Feedback|
|Date:||May 17, 2012|
|Previous Article:||Research and Markets: UK Comms Channel - The Top 250.|
|Next Article:||Research and Markets: Australia Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and...|